5 / 38
Prostate Cancer Clinical States
Aggarwal RR, et al. Oncology (Williston Park). 2017;31:467-474.
Radiographic
Metastases:
ADT resistant
Prechemo
Sipuleucel-T
Abiraterone
Enzalutamide
Radium-223
Recurrent After Initial Hormonal Therapy
Hormone Sensitive
Rising PSA
Salvage regimen,
ADT, or no
therapy
Radiographic
Metastases:
ADT resistant
First-line Chemo
Docetaxel
Localized
Disease
Local therapy
or no therapy
Rising PSA:
ADT resistant
No standard
of care
Overt
Metastases
ADT +
docetaxel or
abiraterone
Radiographic
Metastases:
ADT resistant
Postchemo
Cabazitaxel
Abiraterone
Enzalutamide
Radium-223